These observations render TNF-α and adiponectin as potentially diagnostic biomarkers and appealing therapeutic targets in the setting of NAFLD-associated HCC, possibly in combination with systematic therapy. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.